CECO Environmental Corp. (CECO)

Intra-Cellular Therapies Stock Forecast

Stock Price Forecast

The 5 analysts that cover Intra-Cellular Therapies stock have a consensus rating of "Strong Buy" and an average price target of $42.4, which forecasts a -6.05% decrease in the stock price over the next year. The lowest target is $35 and the highest is $55.

Price Target: $42.40 (-6.05%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$35	$42.4	$40	$55
Change	-22.45%	-6.05%	-11.37%	+21.87%

Analyst Ratings

The average analyst rating for Intra-Cellular Therapies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	3	3	4	4	4	4
Buy	1	1	1	1	1	1
Hold	1	1	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	5	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Amit Dayal HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $33 → $55	Strong Buy	Maintains	$33 → $55	+21.87%	Jul 30, 2025
James Ricchiuti Needham	Needham	Strong Buy Maintains $34 → $44	Strong Buy	Maintains	$34 → $44	-2.50%	Jul 29, 2025
James Ricchiuti Needham	Needham	Strong Buy Maintains $33 → $34	Strong Buy	Maintains	$33 → $34	-24.66%	Apr 30, 2025
Amit Dayal HC Wainwright & Co.	HC Wainwright & Co.	Hold → Strong Buy Upgrades $33	Hold → Strong Buy	Upgrades	$33	-26.88%	Apr 30, 2025
Amit Dayal HC Wainwright & Co.	HC Wainwright & Co.	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Feb 26, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

741.50M

Increased by 32.90%

from 557.93M

Revenue Next Year

808.28M

Increased by 9.01%

from 741.50M

EPS This Year

0.97

Increased by 170.36%

from 0.36

EPS Next Year

1.44

Increased by 47.87%

from 0.97

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	316.01M	324.14M	422.63M	544.85M	557.93M	741.50M	808.28M	853.13M
Revenue Growth	-7.56%	2.57%	30.38%	28.92%	2.40%	32.90%	9.01%	5.55%
EPS	0.23	0.04	0.50	0.37	0.36	0.97	1.44	1.87
EPS Growth	-54.00%	-82.61%	1,150.03%	-26.00%	-2.70%	170.36%	47.87%	29.70%
Forward PE	-	-	-	-	-	46.37	31.36	24.18
No. Analysts	-	-	-	-	-	8	8	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	785.3M	873.9M	878.2M
Avg	741.5M	808.3M	853.1M
Low	689.0M	750.3M	819.7M

Revenue Growth

Revenue Growth	2025	2026	2027
High	40.8%	17.9%	8.7%
Avg	32.9%	9.0%	5.5%
Low	23.5%	1.2%	1.4%

EPS Forecast

EPS	2025	2026	2027
High	1.08	1.61	1.92
Avg	0.97	1.44	1.87
Low	0.81	1.23	1.79

EPS Growth

EPS Growth	2025	2026	2027
High	200.4%	65.7%	33.5%
Avg	170.4%	47.9%	29.7%
Low	125.9%	25.9%	24.6%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.